JP2002528412A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002528412A5 JP2002528412A5 JP2000578001A JP2000578001A JP2002528412A5 JP 2002528412 A5 JP2002528412 A5 JP 2002528412A5 JP 2000578001 A JP2000578001 A JP 2000578001A JP 2000578001 A JP2000578001 A JP 2000578001A JP 2002528412 A5 JP2002528412 A5 JP 2002528412A5
- Authority
- JP
- Japan
- Prior art keywords
- drug
- endoplasmic reticulum
- agent
- protein
- misassembled
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 description 22
- 239000003814 drug Substances 0.000 description 19
- 239000003795 chemical substances by application Substances 0.000 description 17
- 229940079593 drug Drugs 0.000 description 15
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 15
- 102000004169 proteins and genes Human genes 0.000 description 13
- 108090000623 proteins and genes Proteins 0.000 description 13
- 150000001875 compounds Chemical class 0.000 description 10
- 239000013543 active substance Substances 0.000 description 9
- 102000003886 Glycoproteins Human genes 0.000 description 6
- 108090000288 Glycoproteins Proteins 0.000 description 6
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- HSCJRCZFDFQWRP-JZMIEXBBSA-N UDP-alpha-D-glucose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OP(O)(=O)OP(O)(=O)OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](N2C(NC(=O)C=C2)=O)O1 HSCJRCZFDFQWRP-JZMIEXBBSA-N 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 230000005714 functional activity Effects 0.000 description 4
- 108010076513 glycoprotein glycosyltransferase Proteins 0.000 description 4
- 230000031852 maintenance of location in cell Effects 0.000 description 4
- 108091006112 ATPases Proteins 0.000 description 3
- 102000057290 Adenosine Triphosphatases Human genes 0.000 description 3
- 102000034342 Calnexin Human genes 0.000 description 3
- 108010056891 Calnexin Proteins 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 239000000443 aerosol Substances 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102100022548 Beta-hexosaminidase subunit alpha Human genes 0.000 description 1
- 101710205660 Calcium-transporting ATPase Proteins 0.000 description 1
- 101710134161 Calcium-transporting ATPase sarcoplasmic/endoplasmic reticulum type Proteins 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- CNZIQHGDUXRUJS-UHFFFAOYSA-N Cyclopiazonic acid Natural products CC(=C/1C(=O)C2C3C(Cc4cccc5[nH]cc3c45)C(C)(C)N2C1=O)O CNZIQHGDUXRUJS-UHFFFAOYSA-N 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- 101710088235 Envelope glycoprotein C homolog Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000000563 Hyperlipoproteinemia Type II Diseases 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 102100024640 Low-density lipoprotein receptor Human genes 0.000 description 1
- 102000003896 Myeloperoxidases Human genes 0.000 description 1
- 108090000235 Myeloperoxidases Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 208000000733 Paroxysmal Hemoglobinuria Diseases 0.000 description 1
- 102100036050 Phosphatidylinositol N-acetylglucosaminyltransferase subunit A Human genes 0.000 description 1
- 208000022292 Tay-Sachs disease Diseases 0.000 description 1
- 206010045261 Type IIa hyperlipidaemia Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- CNZIQHGDUXRUJS-DQYPLSBCSA-N alpha-cyclopiazonic acid Natural products CC(O)=C1C(=O)[C@@H]2[C@@H]3[C@@H](Cc4cccc5[nH]cc3c45)C(C)(C)N2C1=O CNZIQHGDUXRUJS-DQYPLSBCSA-N 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- ZKSIPEYIAHUPNM-ZEQRLZLVSA-N butobendine Chemical compound C([C@H](CC)N(C)CCN(C)[C@@H](CC)COC(=O)C=1C=C(OC)C(OC)=C(OC)C=1)OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 ZKSIPEYIAHUPNM-ZEQRLZLVSA-N 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 201000001386 familial hypercholesterolemia Diseases 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- BCQZXOMGPXTTIC-UHFFFAOYSA-N halothane Chemical compound FC(F)(F)C(Cl)Br BCQZXOMGPXTTIC-UHFFFAOYSA-N 0.000 description 1
- 229960003132 halothane Drugs 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 201000003045 paroxysmal nocturnal hemoglobinuria Diseases 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10580698P | 1998-10-27 | 1998-10-27 | |
| US60/105,806 | 1998-10-27 | ||
| PCT/US1999/025221 WO2000024391A2 (en) | 1998-10-27 | 1999-10-27 | Conductance of improperly folded proteins through the secretory pathway |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2002528412A JP2002528412A (ja) | 2002-09-03 |
| JP2002528412A5 true JP2002528412A5 (cg-RX-API-DMAC7.html) | 2006-12-28 |
Family
ID=22307893
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000578001A Pending JP2002528412A (ja) | 1998-10-27 | 1999-10-27 | 分泌通路を通る不適当に折り畳まれたタンパク質のコンダクタンス |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US6344475B1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1126832A2 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2002528412A (cg-RX-API-DMAC7.html) |
| AU (1) | AU775575B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2348529A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2000024391A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030236300A1 (en) * | 1999-10-27 | 2003-12-25 | Yale University | Conductance of improperly folded proteins through the secretory pathway and related methods for treating disease |
| US20040266883A1 (en) * | 1999-10-27 | 2004-12-30 | Yale University | Conductance of improperly folded proteins through the secretory pathway and related methods for treating disease |
| US20030149113A1 (en) * | 2001-10-12 | 2003-08-07 | Caplan Michael J. | Conductance of improperly folded proteins through the secretory pathway and related methods for treating disease |
| US20020132770A1 (en) * | 1999-10-27 | 2002-09-19 | Caplan Michael T. | Conductance of improperly folded proteins through the secretory pathway and related methods for treating disease |
| US6867459B2 (en) * | 2001-07-05 | 2005-03-15 | Isonics Corporation | Isotopically pure silicon-on-insulator wafers and method of making same |
| US7119400B2 (en) * | 2001-07-05 | 2006-10-10 | Isonics Corporation | Isotopically pure silicon-on-insulator wafers and method of making same |
| US20040171226A1 (en) * | 2001-07-05 | 2004-09-02 | Burden Stephen J. | Isotopically pure silicon-on-insulator wafers and method of making same |
| US6858615B2 (en) | 2002-02-19 | 2005-02-22 | Parion Sciences, Inc. | Phenyl guanidine sodium channel blockers |
| US20090253714A1 (en) * | 2003-08-20 | 2009-10-08 | Johnson Michael R | Methods of reducing risk of infection from pathogens |
| US7745442B2 (en) | 2003-08-20 | 2010-06-29 | Parion Sciences, Inc. | Methods of reducing risk of infection from pathogens |
| FR2876584B1 (fr) | 2004-10-15 | 2007-04-13 | Centre Nat Rech Scient Cnrse | Utilisation de la kenpaullone pour la fabrication de medicaments pour le traitement de la mucoviscidose et de maladies liees a un defaut d'adressage des proteines dans les cellules |
| US8859020B2 (en) | 2005-05-30 | 2014-10-14 | Benny Antony | Treatment of alzheimer's with a curcuminoid mixture and essential oil of turmeric having 45% Ar-turmerone |
| US10286027B2 (en) | 2005-05-30 | 2019-05-14 | Arjuna Natural Extracts, Ltd. | Sustained release formulations of curcuminoids and method of preparation thereof |
| US7883728B2 (en) | 2005-05-30 | 2011-02-08 | Arjuna Natural Extracts, Ltd. | Composition to enhance the bioavailability of curcumin |
| US10543277B2 (en) | 2005-05-30 | 2020-01-28 | Arjuna Natural Private Limited | Formulation of curcumin with enhanced bioavailability of curcumin and method of preparation and treatment thereof |
| US12053438B2 (en) | 2005-05-30 | 2024-08-06 | Arjuna Natural Private Limited | Formulation of curcuminoids with enhanced bioavailability of curcumin, demethoxycurcumin, bisdemethoxycurcumin and method of preparation and uses thereof |
| US9492402B2 (en) | 2005-05-30 | 2016-11-15 | Benny Antony | Formulation of curcuminoids with enhanced bioavailability of curcumin, demethoxycurcumin, bisdemethoxycurcumin and method of preparation and uses thereof |
| DK1890546T3 (en) | 2005-05-30 | 2019-03-11 | Benny Antony | Process for improving the bioavailability of curcumin |
| US20070021433A1 (en) | 2005-06-03 | 2007-01-25 | Jian-Qiang Fan | Pharmacological chaperones for treating obesity |
| EP2190850A4 (en) * | 2007-07-03 | 2011-03-09 | Univ British Columbia | DELTAF508 CFTR DELTAF508 DELTAFLECTIVE TRANSPORTATION MOLECULES |
| GB0809360D0 (en) * | 2008-05-22 | 2008-07-02 | Isis Innovation | Calcium modulation |
| AR086745A1 (es) | 2011-06-27 | 2014-01-22 | Parion Sciences Inc | 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil)carbamimidoil)pirazina-2-carboxamida |
| HUE032891T2 (hu) | 2012-12-17 | 2017-11-28 | Parion Sciences Inc | Klórpirazin-karboxamid-származékok nem kielégítõ nyálkahártya-hidratáció által elõsegített megbetegedések kezelésére |
| RU2671976C2 (ru) | 2012-12-17 | 2018-11-08 | Пэрион Сайенсиз, Инк. | Соединения 3,5-диамино-6-хлор-n-(n-(4-фенилбутил)карбамимидоил)пиразин-2-карбоксамида |
| US9102633B2 (en) | 2013-12-13 | 2015-08-11 | Parion Sciences, Inc. | Arylalkyl- and aryloxyalkyl-substituted epithelial sodium channel blocking compounds |
| RU2637101C2 (ru) * | 2016-01-11 | 2017-11-29 | Федеральное государственное бюджетное научное учреждение "Федеральный исследовательский центр вирусологии и микробиологии" (ФГБНУ ФИЦВиМ) | Устройство для определения аспирированной дозы аэрозолей |
| CN116240239B (zh) * | 2023-04-18 | 2024-12-27 | 华东师范大学 | 程序可控的蛋白质快速分泌释放系统及其构建方法和应用 |
| CN116476541B (zh) * | 2023-05-16 | 2025-12-02 | 征图新视(江苏)科技股份有限公司 | 一种针对光学膜卷材的高速打标系统 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8704089D0 (en) | 1987-02-21 | 1987-03-25 | Fisons Plc | Method of treatment |
| US5674898A (en) * | 1990-03-05 | 1997-10-07 | Genzyme Corporation | Methods and therapeutic compositions for treating cystic fibrosis |
| US6274148B1 (en) * | 1990-11-08 | 2001-08-14 | Chiron Corporation | Hepatitis C virus asialoglycoproteins |
| WO1993013768A1 (en) | 1992-01-06 | 1993-07-22 | Ariad Pharmaceuticals, Inc. | Therapeutic uses of thiol-oxidizing agents and sulfhydryl-alkylating agents |
| US5384128A (en) | 1993-03-02 | 1995-01-24 | University Of Alabama Research Foundation | Method of and compounds for treatment for cystic fibrosis |
| US5994341A (en) | 1993-07-19 | 1999-11-30 | Angiogenesis Technologies, Inc. | Anti-angiogenic Compositions and methods for the treatment of arthritis |
| US5691306A (en) | 1993-08-26 | 1997-11-25 | National Research Council Of Canada | Methods of detection and treatment of protein trafficking disorders and increasing secretory protein production |
| DE69535673D1 (de) * | 1994-08-30 | 2008-02-07 | Univ Dundee | Mittel zur induktion von apoptosis und zur therapieanwendung |
| WO1996036334A1 (en) * | 1995-05-19 | 1996-11-21 | University Of East Anglia | Use of calcium intracellular store inactivators and formulations thereof as cell growth inhibitors |
| US6025339A (en) * | 1995-06-07 | 2000-02-15 | East Carolina University | Composition, kit and method for treatment of disorders associated with bronchoconstriction and lung inflammation |
| US6015828A (en) | 1996-05-31 | 2000-01-18 | Cuppoletti; John | Chemical modification of chloride channels as a treatment for cystic fibrosis and other diseases |
| US5985824A (en) | 1997-02-27 | 1999-11-16 | Genzyme Corporation | Methods and compositions for treating cystic fibrosis |
-
1999
- 1999-10-27 AU AU12370/00A patent/AU775575B2/en not_active Expired
- 1999-10-27 US US09/427,696 patent/US6344475B1/en not_active Expired - Lifetime
- 1999-10-27 JP JP2000578001A patent/JP2002528412A/ja active Pending
- 1999-10-27 EP EP99970919A patent/EP1126832A2/en not_active Ceased
- 1999-10-27 WO PCT/US1999/025221 patent/WO2000024391A2/en not_active Ceased
- 1999-10-27 CA CA002348529A patent/CA2348529A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Yagiela et al. | Comparison of myotoxic effects of lidocaine with epinephrine in rats and humans | |
| Mackenzie et al. | Current strategies for retarding progression of renal disease | |
| Lau et al. | Inhibition of caspase-mediated apoptosis by peroxynitrite in traumatic brain injury | |
| Malmqvist et al. | Angiotensin II type 1 (AT1) receptor blockade in hypertensive women: benefits of candesartan cilexetil versus enalapril or hydrochlorothiazide | |
| EE200100505A (et) | Modifitseeritud tärklise kasutamine hüdrofiilses kontrollitud vabanemisega preparaadis, hüdrofiilnekontrollitud vabanemisega preparaat, selle valmistamismeetod ja kasutamine ning ravimvorm | |
| IE61182B1 (en) | Pharmaceutical compositions containing ibuprofen in combination with a piperidinoalkanol antihistamine | |
| Morisco et al. | Efficacy and tolerability of lercanidipine in comparison to and in combination with atenolol in patients with mild to moderate hypertension in a double-blind controlled study | |
| Policicchio et al. | Efficacy and tolerability of lercanidipine in patients with mild to moderate essential hypertension: a comparative study with slow-release nifedipine | |
| Rengo et al. | Activity of lercanidipine in double-blind comparison with nitrendipine in combination treatment of patients with resistant essential hypertension | |
| Goa et al. | Lisinopril: A review of its pharmacology and use in the management of the complications of diabetes mellitus | |
| Brogden et al. | Moexipril: a review of its use in the management of essential hypertension | |
| McKeage et al. | Manidipine: a review of its use in the management of hypertension | |
| Cogolludo et al. | New insights in the pharmacological therapy of arterial hypertension | |
| Ninci et al. | Efficacy and tolerability of lercanidipine in elderly patients with mild to moderate hypertension in a placebo-controlled, double-blind study | |
| AU2003287488B2 (en) | Pharmaceutical compositions and dosage forms for buccal and sublingual delivery of tizanidine and methods of administering tizanidine sublingually or bucally | |
| Messerli | Moxonidine: a new and versatile antihypertensive | |
| Noa et al. | A comparative study of policosanol vs lovastatin on intimal thickening in rabbit cuffed carotid artery | |
| Manolis et al. | Angiotensin II receptor antagonist telmisartan in isolated systolic hypertension (ARAMIS) study: efficacy and safety of telmisartan 20, 40 or 80 mg versus hydrochlorothiazide 12.5 mg or placebo | |
| Malhotra et al. | Barnidipine | |
| MXPA02009819A (es) | El uso de un bloqueante de los canales de calcio para tratamiento de trastornos renales. | |
| JPH10510528A (ja) | 骨関節炎を治療するためのジクロフェナック及びトリベノサイドの併用 | |
| JP2002503687A5 (cg-RX-API-DMAC7.html) | ||
| Anderson et al. | Ramipril: a review of its use in preventing cardiovascular outcomes in high-risk patients | |
| Fenton et al. | Telmisartan/hydrochlorothiazide: in the treatment of essential hypertension | |
| Lee et al. | Systemic absorption of insulin from a Gelfoam® ocular device |